Evidence map›Paper›PMID 42108434›Full record

ArticleBMC pregnancy and childbirth2026

Cohort study on transplacental antibody transfer to fetal growth-restricted infants of tdap-vaccinated pregnant women, study protocol.

Sem J Teijsse, Hester E de Melker, Nynke Y Rots, Gerco den Hartog, Pieter G M van Gageldonk, Renate G van der Molen, Cecile A C M van Els, Nicoline A T van der Maas

Abstract read
In one paragraph

Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sem J TeijsseCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, Bilthoven, 3720 MA, The Netherlands. sem.teijsse@rivm.nl.
Hester E de MelkerCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, Bilthoven, 3720 MA, The Netherlands.
Nynke Y RotsCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, Bilthoven, 3720 MA, The Netherlands.
Gerco den HartogCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, Bilthoven, 3720 MA, The Netherlands.
Pieter G M van GageldonkCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, Bilthoven, 3720 MA, The Netherlands.
Renate G van der MolenDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center, Nijmegen, The Netherlands.
Cecile A C M van ElsCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, Bilthoven, 3720 MA, The Netherlands.
Nicoline A T van der MaasCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Antonie van Leeuwenhoeklaan 9, Bilthoven, 3720 MA, The Netherlands.

Funding

the Netherlands Organisation for Health Research and Development (ZonMw) 10150022310029
6 · The paper itself

Abstract

backgroundPertussis is endemic with epidemic peaks affecting all age groups and is a severe disease in infants too young to be vaccinated. Maternal tetanus-diphtheria-acellular-pertussis (Tdap)-vaccination has an estimated vaccine effectiveness against pertussis disease of approximately 90% for infants up to 2 months, thus shortening the vulnerable period. Maternal vaccination protects through transplacental transfer of maternal antibodies via an active receptor-mediated process. This process may be impaired in fetuses with fetal growth restriction (FGR), primarily caused by placental insufficiency. In the Netherlands, term infants from mothers Tdap-vaccinated during pregnancy receive diphtheria, tetanus, and pertussis, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B (DTaP-IPV-Hib-HepB) vaccinations at age 3-5-12 months. Infants born preterm or from unvaccinated mothers are recommended to receive an extra dose at 2 months-of-age. For term FGR infants from vaccinated mothers this 3-5-12 month schedule may be suboptimal due to compromised placental function, including transplacental transfer of maternal antibodies. Consequently, protection from maternal vaccination up to their first vaccination may be less optimal compared to term infants who are appropriate for gestational age (AGA) or small for gestational age (SGA).

aimThis study investigates whether following maternal Tdap vaccination, concentrations of passively acquired maternal IgG antibodies against Tdap vaccine antigens in 2-month-old FGR infants are at least as high as in 2-month-old term AGA- and SGA infants.

methodThis is a prospective, observational cohort study involving Tdap-vaccinated pregnant women carrying a fetus with signs of SGA or FGR. Blood samples will be collected from mothers (finger-stick) and their infants (umbilical cord) at birth, and at 2 months (heel-stick), to measure Tdap-specific IgG antibody concentrations. Additionally, questionnaire data on general health will be gathered at three different time points. Results will be compared with historical studies investigating transfer of maternal antibodies after Tdap vaccination during pregnancy in AGA preterms and terms. DISCUSSION: By comparing the concentrations of IgG antibodies against Tdap vaccine antigens among FGR, SGA, AGA preterms and terms, we will contribute to insights into the necessity of optimizing the immunization schedule for FGR infants.

Indexed as

Antibodies, BacterialDiphtheria-Tetanus-acellular Pertussis VaccinesFetal Growth RetardationImmunity, Maternally-AcquiredMaternal-Fetal ExchangeAdultCohort StudiesFemaleHumansInfantInfant, NewbornNetherlandsPregnancyVaccinationWhooping CoughAntibodies, BacterialDiphtheria-Tetanus-acellular Pertussis VaccinesFetal growth restrictionLow birthweightPlacental antibody transferPlacental insufficiencySmall for gestational age

Identifiers

PMID42108434
PMCPMC13330358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.